SKIN Earnings Prediction
The chart below shows how SKIN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SKIN sees a +5.50% change in stock price 10 days leading up to the earnings, and a -2.49% change 10 days following the report. On the earnings day itself, the stock moves by -0.62%. This data can give you a slight idea of what to expect for the next quarter's release.
SKIN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
78.80M
-19.11%
-13.02%
Gross Margin
51.58%
500.16%
14.14%
Operating Margin
-27.30%
-67.61%
11.84%
Net Margin
-23.21%
-69.37%
-10650.00%
EPS
-0.15
-73.21%
--
No Data Available
SKIN Earnings Analysis
The Beauty Health Company Class A Common Stock Corporation (SKIN.O) Earnings Conference Call
Positive
Strong Q3 Performance: Third quarter revenue came in above the midpoint of our guidance, we lowered our operating expenses versus the prior year and delivered profitable adjusted EBITDA despite top line pressure across device sales.
Improved Adjusted Gross Margin: Strong growth in consumables allowed us to make great strides in improving our adjusted gross margin to 69%.
Cash Position and Debt Repurchase: We ended the quarter with approximately $359 million in cash, having deployed $156 million of cash to repurchase $192 million of our convertible debt.
Gross Margin Improvement Efforts: We achieved adjusted gross margin in the upper 60s as we continue to focus on gross margin improvement programs for manufacturing to drive further efficiency and cost effectiveness in our operations.
Market Reception of Innovation: We are excited about the reception by the market to our latest innovation, the HydraFacial HydraLoc HA Booster, the first in our portfolio to be backed by extensive clinical claims.
Negative
Strong Q3 Performance: Third quarter revenue came in above the midpoint of our guidance, we lowered our operating expenses versus the prior year and delivered profitable adjusted EBITDA despite top line pressure across device sales.
Revenue Decline Analysis: We saw a decline in revenue of 19.1% year over year, totaling $78.8 million, indicating a significant drop in financial performance.
Equipment Sales Decline: Global equipment sales declined 45.9%, offset by a 10.4% increase in consumable sales, highlighting a major weakness in the equipment segment.
Americas Unit Sales Decline: In the Americas, we sold 634 units compared to 776 units in Q3 of 2023, reflecting a decrease in market demand.
China Revenue Decline: The decline in China accounted for a revenue drop of 68.5% year-over-year, indicating severe challenges in that market.
SKIN FAQs
How does SKIN typically perform around its earnings report dates?
Is The Beauty Health Company (SKIN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SKIN Earning Call Sentiment
The Beauty Health Company (SKIN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SKIN.O
2.07%Positive
The earnings call indicates a significant year-over-year revenue decline, ongoing operational risks, and pressure in international markets. While there are improvements in gross margin and cash position, the weak guidance and lack of clarity on future growth plans negatively impact sentiment. The Q&A section reinforces concerns about international market challenges and declining gross margins in Q4. Despite some positive aspects like consumable sales growth and debt repurchase, the overall sentiment remains negative, suggesting a potential stock price decline of -2% to -8% over the next two weeks.